Marinus Pharmaceuticals (MRNS) Receives Daily News Impact Rating of 0.18

News stories about Marinus Pharmaceuticals (NASDAQ:MRNS) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Marinus Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.9595846026836 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of research analysts have weighed in on the stock. JMP Securities reaffirmed an “outperform” rating and issued a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Tuesday, September 12th. ValuEngine raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 11th.

Marinus Pharmaceuticals (NASDAQ MRNS) traded down 4.29% during mid-day trading on Friday, hitting $5.58. 471,221 shares of the stock were exchanged. The company’s market cap is $145.50 million. Marinus Pharmaceuticals has a one year low of $0.82 and a one year high of $8.22. The company has a 50-day moving average price of $4.61 and a 200-day moving average price of $2.34.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. Analysts forecast that Marinus Pharmaceuticals will post ($0.74) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/2957613/marinus-pharmaceuticals-mrns-receives-daily-news-impact-rating-of-0-18.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Insider Buying and Selling by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.